Denali Therapeutics (DNLI) drew fresh interest after publishing Phase 1/2 trial results for its Hunter syndrome therapy, tividenofusp alfa, in The New England Journal of Medicine, alongside ongoing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results